Does Local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review

European Urology

Volumn 58, Issue 2, 2010, Pages 261-269

  Verhagen, Paul C M S ^a   Schröder, Fritz H ^a   Collette, Laurence ^b   Bangma, Chris H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b European Organisation of Research and Treatment of Cancer   (Belgium)

Author keywords

Androgen deprivation therapy; Prostate cancer

Indexed keywords

FLUTAMIDE; GONADORELIN DERIVATIVE;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; HUMAN; LOCAL THERAPY; LYMPH NODE METASTASIS; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

COMBINED MODALITY THERAPY; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77954492251     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.05.027     Document Type: Review

References (36)

1. C. Huggins, and C.V. Hodges Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941 J Urol 168 2002 9 12
2. P. Niehans Prostata Krebs wie Paraprostata-Hypertrophie sind Folgen hormonaler Störungen die wir je früher je besser beeinflussen können 1940 Verlag Hans Huber Bern
3. B. Nair, T. Wilt, R. MacDonald, and I. Rutks Early versus deferred androgen suppression in the treatment of advanced prostatic cancer Cochrane Database Syst Rev 2002 CD003506
4. S. Kumar, M. Shelley, and C. Harrison Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer Cochrane Database Syst Rev 2006 CD006019
5. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial JAMA 294 2005 1233 1239
6. M. Milosevic, P. Chung, and C. Parker Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response Cancer Res 67 2007 6022 6025
7. E.M. Messing, J. Manola, and J. Yao Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 2006 472 479
8. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
9. N. Mantel, and W. Haenszel Statistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 22 1959 719 748
10. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
11. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
12. D.G. McLeod, P. Iversen, and W.A. See Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer BJU Int 97 2006 247 254
13. M.P. Wirth, L. Weissbach, and F.-J. Marx Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer Eur Urol 45 2004 267 270 discussion 270
14. G.K. Zagars, D.E. Johnson, A.C. von Eschenbach, and D.H. Hussey Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study Int J Radiat Oncol Biol Phys 14 1988 1085 1091
15. W.P. Jordan Jr., C.E. Blackard, and D.P. Byar Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma South Med J 70 1977 1411 1413
16. P. Iversen, J.E. Johansson, and P. Lodding Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6 J Urol 172 2004 1871 1876
17. D.P. Byar Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate Cancer 32 1973 1126 1130
18. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997; 79:235-46.
19. D. Kirk Timing and choice of androgen ablation Prostate Cancer Prostatic Dis 7 2004 217 222
20. F.H. Schröder, K.-H. Kurth, and S.D. Fossa Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846 - a phase III study J Urol 172 2004 923 927
21. F.H. Schroder, K.H. Kurth, and S.D. Fossa Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer Protocol 30846 after 13 years of follow-up (a randomised controlled trial) Eur Urol 55 2009 14 22 editorial 23-25
22. U.E. Studer, D. Hauri, and S. Hanselmann Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88 J Clin Oncol 22 2004 4109 4118
23. U.E. Studer, P. Whelan, and W. Albrecht Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891 J Clin Oncol 24 2006 1868 1876
24. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103 106
25. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
26. A.V. D'Amico, M.H. Chen, A.A. Renshaw, M. Loffredo, and P.W. Kantoff Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289 295
27. T. Granfors, H. Modig, J.E. Damber, and R. Tomic Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone J Urol 176 2006 544 547
28. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
29. M. Roach III, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591
30. J.W. Denham, A. Steigler, and D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncol 6 2005 841 850
31. C.A. Lawton, M. DeSilvio, and M. Roach III An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655
32. A. Widmark, O. Klepp, and A. Solberg Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 373 2009 301 308
33. M.V. Pilepich, K. Winter, and M.J. John Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
34. J. Engel, P.J. Bastian, and H. Baur Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer Eur Urol 57 2010 754 761
35. J.J. Coen, A.L. Zietman, H. Thakral, and W.U. Shipley Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases J Clin Oncol 20 2002 3199 3205
36. U.E. Studer, L. Collette, and P. Whelan Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891) Eur Urol 53 2008 941 949